192:@0.017061:0.038809:0.056572:0.038809:0.056572:0.019212:0.017061:0.019212:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Sorafenib and sunitinib:@0.084848:0.079455:0.319178:0.079455:0.319178:0.061640:0.084848:0.061640:0.011118:0.013683:0.006842:0.014111:0.005987:0.013683:0.012828:0.005131:0.014111:0.005987:0.014111:0.012828:0.014111:0.005987:0.009407:0.012828:0.012828:0.005131:0.006414:0.005131:0.012828:0.005131:0.014111
Sorafenib and sunitinib are small molecu-:@0.084848:0.096036:0.475760:0.096036:0.475760:0.080280:0.084848:0.080280:0.009583:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.007068:0.013143:0.011738:0.013181:0.007072:0.007466:0.011699:0.011738:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.007081:0.013143:0.005713:0.012508:0.007070:0.007466:0.018049:0.013143:0.003848:0.003848:0.007081:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.006388
lar TKIs involved in cellular pathways such :@0.084848:0.111474:0.481088:0.111474:0.481088:0.095718:0.084848:0.095718:0.003848:0.013143:0.005792:0.006696:0.008197:0.011372:0.004349:0.007466:0.006696:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.006696:0.003848:0.011738:0.006696:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.006696:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.007466:0.006696:0.007466:0.011699:0.012450:0.011738:0.005330
as the Raf/MEK/ERK pathway (MAP kinase :@0.084848:0.126912:0.481088:0.126912:0.481088:0.111156:0.084848:0.111156:0.013143:0.007466:0.005272:0.006523:0.011738:0.012508:0.005272:0.011680:0.013143:0.006042:0.008409:0.017684:0.010314:0.011372:0.008409:0.010314:0.011680:0.011372:0.005272:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.005272:0.007100:0.017684:0.014239:0.011392:0.005272:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.005330
pathway) as well as cell-surface kinases :@0.084848:0.142351:0.481088:0.142351:0.481088:0.126595:0.084848:0.126595:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.007100:0.009506:0.013143:0.007466:0.009506:0.015990:0.012508:0.003848:0.003848:0.009506:0.013143:0.007466:0.009506:0.012450:0.012508:0.003848:0.003848:0.006388:0.007466:0.011699:0.006716:0.006042:0.013143:0.012450:0.012508:0.009506:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007466:0.005330
such as the VEGFRs and platelet-derived :@0.084848:0.157789:0.481094:0.157789:0.481094:0.142033:0.084848:0.142033:0.007466:0.011699:0.012450:0.011738:0.007793:0.013143:0.007466:0.007793:0.006523:0.011738:0.012508:0.007780:0.013508:0.010314:0.016779:0.009333:0.011680:0.007466:0.007793:0.013143:0.011738:0.013181:0.007793:0.013123:0.003848:0.013143:0.006523:0.012508:0.003848:0.012508:0.006523:0.006388:0.013181:0.012508:0.005792:0.003848:0.010660:0.012508:0.013181:0.005330
growth  factor  (PDGF) receptor-beta.  :@0.084848:0.173228:0.481087:0.173206:0.481087:0.157450:0.084848:0.157472:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.005330:0.014128:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.005330:0.014126:0.007100:0.011392:0.014316:0.016779:0.009333:0.007100:0.019473:0.005711:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.006388:0.013123:0.012508:0.006523:0.013143:0.005330:0.006199:0.749769
4:@0.469540:0.167587:0.475755:0.167587:0.475755:0.158401:0.469540:0.158401:0.006215
These kinases are involved in angiogene-:@0.084848:0.188644:0.475757:0.188644:0.475757:0.172888:0.084848:0.172888:0.008197:0.011738:0.012508:0.007466:0.012508:0.007254:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007466:0.007268:0.013143:0.005713:0.012508:0.007254:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.007268:0.003848:0.011738:0.007254:0.013143:0.011738:0.012950:0.003848:0.012604:0.012950:0.012508:0.011738:0.012502:0.006388
sis, invasion of the tumour and tumour me-:@0.084848:0.204083:0.475749:0.204083:0.475749:0.188327:0.084848:0.188327:0.007466:0.003848:0.007466:0.005330:0.004945:0.003848:0.011738:0.010660:0.013143:0.007466:0.003848:0.012604:0.011738:0.004945:0.012604:0.006042:0.004945:0.006523:0.011738:0.012508:0.004945:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.004932:0.013143:0.011738:0.013181:0.004945:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.004932:0.018049:0.012508:0.006388
tastasis, all of which are inhibited by :@0.084848:0.219521:0.481087:0.219521:0.481087:0.203765:0.084848:0.203765:0.006523:0.013143:0.007466:0.006523:0.013143:0.007466:0.003848:0.007466:0.005330:0.014932:0.013143:0.003848:0.003848:0.014932:0.012604:0.006042:0.014932:0.015990:0.011738:0.003848:0.012450:0.011738:0.014932:0.013143:0.005715:0.012508:0.014932:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012508:0.013181:0.014932:0.013123:0.010314:0.005330
sorafenib and sunitinib.  Sorafenib  is indi-:@0.084848:0.234959:0.475759:0.234942:0.475759:0.219186:0.084848:0.219203:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.008505:0.013143:0.011738:0.013181:0.008505:0.007466:0.011699:0.011738:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.006208:0.008505:0.009583:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.005330:0.003165:0.003848:0.007466:0.008505:0.003848:0.011738:0.013181:0.003848:0.666358
4:@0.305337:0.229323:0.311552:0.229323:0.311552:0.220137:0.305337:0.220137:0.006215
cated for the treatment of advanced re-:@0.084840:0.250380:0.475774:0.250380:0.475774:0.234624:0.084840:0.234624:0.012450:0.013143:0.006523:0.012508:0.013181:0.006908:0.006042:0.012604:0.005792:0.006908:0.006523:0.011738:0.012508:0.006908:0.006523:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006898:0.012604:0.006042:0.006908:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.006908:0.005713:0.012508:0.006388
nal cell cancer and advanced inoperable :@0.084840:0.265819:0.481085:0.265819:0.481085:0.250063:0.084840:0.250063:0.011738:0.013143:0.003848:0.004233:0.012450:0.012508:0.003848:0.003848:0.004233:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.004220:0.013143:0.011738:0.013181:0.004233:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.004233:0.003848:0.011738:0.012604:0.013123:0.012508:0.005792:0.013143:0.013123:0.003848:0.012508:0.005330
hepatocellular  cancer  and  locally ad-:@0.084840:0.281257:0.475746:0.281257:0.475746:0.265501:0.084840:0.265501:0.011738:0.012508:0.013123:0.013143:0.006523:0.012604:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.005330:0.008472:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.008467:0.013143:0.011738:0.013181:0.005330:0.008476:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.013816:0.013143:0.013181:0.006388
vanced or metastatic differentiated thy-:@0.084840:0.296696:0.475748:0.296696:0.475748:0.280940:0.084840:0.280940:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.009082:0.012604:0.005792:0.009082:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.009082:0.013181:0.003848:0.006104:0.006042:0.012508:0.005709:0.012508:0.011738:0.006523:0.003848:0.013143:0.006523:0.012508:0.013181:0.009082:0.006523:0.011738:0.010314:0.006388
roid cancer, whereas sunitinib is indicated :@0.084840:0.312134:0.481068:0.312134:0.481068:0.296378:0.084840:0.296378:0.005713:0.012604:0.003848:0.013181:0.005907:0.012450:0.013143:0.011738:0.012450:0.012508:0.003766:0.005330:0.005907:0.015990:0.011738:0.012508:0.005711:0.012508:0.013143:0.007466:0.005907:0.007466:0.011699:0.011738:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.005907:0.003848:0.007466:0.005907:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330
for the treatment of metastatic renal cell :@0.084840:0.327572:0.481085:0.327572:0.481085:0.311816:0.084840:0.311816:0.006042:0.012604:0.005792:0.007337:0.006523:0.011738:0.012508:0.007339:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.007341:0.012604:0.006042:0.007341:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.007351:0.005713:0.012508:0.011738:0.013143:0.003848:0.007351:0.012450:0.012508:0.003848:0.003848:0.005330
cancer  after  failure of  cytokine-based :@0.084840:0.343011:0.481083:0.343011:0.481083:0.327255:0.084840:0.327255:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.009146:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.009146:0.006042:0.013143:0.003848:0.003848:0.011699:0.005719:0.012508:0.014490:0.012604:0.006042:0.005330:0.009148:0.012450:0.010314:0.006523:0.012604:0.009660:0.003848:0.011738:0.012508:0.006388:0.013123:0.013143:0.007466:0.012508:0.013181:0.005330
therapy  (interferon-alpha and IL-2) and :@0.084840:0.358449:0.481095:0.358449:0.481095:0.342693:0.084840:0.342693:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006127:0.007100:0.003848:0.011738:0.006523:0.012508:0.006708:0.006042:0.012508:0.005711:0.012604:0.011738:0.006388:0.013143:0.003848:0.013123:0.011738:0.013143:0.011468:0.013143:0.011738:0.013181:0.011468:0.004349:0.008890:0.006388:0.010660:0.007100:0.011468:0.013143:0.011738:0.013181:0.005330
GIST after failure of imatinib treatment due :@0.084840:0.373888:0.481099:0.373888:0.481099:0.358132:0.084840:0.358132:0.016779:0.004349:0.009583:0.008197:0.004637:0.013143:0.006042:0.006523:0.012508:0.005792:0.004637:0.006042:0.013143:0.003848:0.003848:0.011699:0.005721:0.012508:0.004637:0.012604:0.006042:0.004637:0.003848:0.018049:0.013143:0.006523:0.003848:0.011738:0.003848:0.013123:0.004637:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.004637:0.013181:0.011699:0.012508:0.005330
to resistance or intolerability.:@0.084840:0.389326:0.348546:0.389326:0.348546:0.373570:0.084840:0.373570:0.006523:0.012604:0.005330:0.005703:0.012508:0.007466:0.003848:0.007466:0.006523:0.013143:0.011738:0.012450:0.012508:0.005330:0.012604:0.005792:0.005330:0.003848:0.011738:0.006523:0.012604:0.003848:0.012508:0.005792:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330
4,13:@0.348548:0.383663:0.370300:0.383663:0.370300:0.374477:0.348548:0.374477:0.006215:0.003107:0.006215:0.006215
 :@0.370306:0.389282:0.375636:0.389282:0.375636:0.373526:0.370306:0.373526:0.005330
Side effects of the small molecular inhibi-:@0.103029:0.404720:0.475746:0.404720:0.475746:0.388965:0.103029:0.388965:0.009583:0.003848:0.013181:0.012508:0.004291:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.004291:0.012604:0.006042:0.004291:0.006523:0.011738:0.012508:0.004291:0.007466:0.018049:0.013143:0.003848:0.003848:0.004306:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.013143:0.005792:0.004291:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006388
tor include nausea and vomiting, skin rash, :@0.084844:0.420159:0.481080:0.420159:0.481080:0.404403:0.084844:0.404403:0.006523:0.012604:0.005792:0.004530:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.004541:0.011738:0.013143:0.011699:0.007466:0.012508:0.013143:0.004541:0.013143:0.011738:0.013181:0.004541:0.010660:0.012604:0.018049:0.003848:0.006523:0.003848:0.011738:0.012950:0.005330:0.004530:0.007466:0.009660:0.003848:0.011738:0.004541:0.005792:0.013143:0.007466:0.011738:0.005330:0.005330
fatigue, asthenia and bleeding complica-:@0.084844:0.435597:0.475754:0.435597:0.475754:0.419841:0.084844:0.419841:0.006042:0.013143:0.006523:0.003848:0.012950:0.011699:0.012508:0.005330:0.005272:0.013143:0.007466:0.006523:0.011738:0.012508:0.011738:0.003848:0.013143:0.005272:0.013143:0.011738:0.013181:0.005272:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.005272:0.012450:0.012604:0.018049:0.013123:0.003848:0.003848:0.012450:0.013143:0.006388
tions.  The  use of sorafenib can further :@0.084844:0.451036:0.481114:0.451018:0.481114:0.435262:0.084844:0.435280:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006216:0.011796:0.008197:0.011738:0.012508:0.005330:0.006456:0.011699:0.007466:0.012508:0.011796:0.012604:0.006042:0.011796:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.011796:0.012450:0.013143:0.011738:0.011796:0.006042:0.011699:0.005792:0.006523:0.011738:0.012508:0.005792:0.345652
4:@0.132353:0.445399:0.138568:0.445399:0.138568:0.436214:0.132353:0.436214:0.006215
lead to hypophosphataemia, whereas su-:@0.084845:0.466602:0.475757:0.466602:0.475757:0.450846:0.084845:0.450846:0.003848:0.012508:0.013143:0.013181:0.005311:0.006523:0.012604:0.005299:0.011738:0.010314:0.013123:0.012604:0.013123:0.011738:0.012604:0.007466:0.013123:0.011738:0.013143:0.006523:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.005311:0.015990:0.011738:0.012508:0.005709:0.012508:0.013143:0.007466:0.005311:0.007466:0.011699:0.006388
nitinib use  may  lead to  cardiotoxicity  or :@0.084845:0.482186:0.481102:0.482186:0.481102:0.466430:0.084845:0.466430:0.011738:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.009448:0.011699:0.007466:0.012508:0.005330:0.004106:0.018049:0.013143:0.010314:0.005330:0.004104:0.003848:0.012508:0.013143:0.013181:0.009448:0.006523:0.012604:0.005330:0.004097:0.012450:0.013143:0.005677:0.013181:0.003848:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.005330:0.004104:0.012604:0.005792:0.005330
congestive heart failure.:@0.084845:0.497770:0.310582:0.497770:0.310582:0.482014:0.084845:0.482014:0.012450:0.012604:0.011738:0.012950:0.012508:0.007466:0.006523:0.003848:0.010660:0.012508:0.005330:0.011738:0.012508:0.013143:0.005792:0.006523:0.005330:0.006042:0.013143:0.003848:0.003848:0.011699:0.005700:0.012508:0.005330
4:@0.310580:0.492142:0.316795:0.492142:0.316795:0.482956:0.310580:0.482956:0.006215
Axitinib:@0.084848:0.529982:0.161390:0.529982:0.161390:0.512166:0.084848:0.512166:0.015822:0.011973:0.005131:0.006414:0.005131:0.012828:0.005131:0.014111
Axitinib is a TKI including VEGFR-1, VEGFR-2 :@0.084848:0.546709:0.481078:0.546709:0.481078:0.530953:0.084848:0.530953:0.014239:0.009236:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.004695:0.003848:0.007466:0.004695:0.013143:0.004695:0.008197:0.011372:0.004349:0.004686:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.004695:0.013508:0.010314:0.016779:0.009333:0.011680:0.006388:0.010660:0.005330:0.004695:0.013508:0.010314:0.016779:0.009333:0.011680:0.006388:0.010660:0.005330
and VEGFR-3.  Axitinib is indicated for the :@0.084848:0.562293:0.481102:0.562290:0.481102:0.546534:0.084848:0.546537:0.013143:0.011738:0.013181:0.004483:0.013508:0.010314:0.016779:0.009333:0.011680:0.006388:0.010660:0.005330:0.018648:0.004483:0.014239:0.009236:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.004483:0.003848:0.007466:0.004483:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.004474:0.006042:0.012604:0.005792:0.004466:0.006523:0.011738:0.012508:0.183814
132:@0.211383:0.556671:0.230028:0.556671:0.230028:0.547486:0.211383:0.547486:0.006215:0.006215:0.006215
treatment  of advanced renal cell carci-:@0.084851:0.577874:0.475762:0.577874:0.475762:0.562118:0.084851:0.562118:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.003760:0.012604:0.006042:0.009102:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.009102:0.005713:0.012508:0.011738:0.013143:0.003848:0.009102:0.012450:0.012508:0.003848:0.003848:0.009102:0.012450:0.013143:0.005659:0.012450:0.003848:0.006388
noma  after  failure  of  one  prior  systemic :@0.084851:0.593458:0.481075:0.593458:0.481075:0.577702:0.084851:0.577702:0.011738:0.012604:0.018049:0.013143:0.005330:0.004549:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.004545:0.006042:0.013143:0.003848:0.003848:0.011699:0.005719:0.012508:0.005330:0.004551:0.012604:0.006042:0.005330:0.004551:0.012604:0.011738:0.012508:0.005330:0.004545:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.004545:0.007466:0.010314:0.007466:0.006523:0.012508:0.018049:0.003848:0.012450:0.005330
therapy.:@0.084851:0.609042:0.163321:0.609042:0.163321:0.593286:0.084851:0.593286:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
Ibrutinib :@0.084848:0.641254:0.174219:0.641254:0.174219:0.623438:0.084848:0.623438:0.005987:0.014111:0.006842:0.012828:0.006414:0.005131:0.012828:0.005131:0.014111:0.005987
Ibrutinib is a small-molecule inhibitor of BTK :@0.084848:0.657981:0.481046:0.657981:0.481046:0.642225:0.084848:0.642225:0.004156:0.012931:0.005600:0.011507:0.006331:0.003656:0.011545:0.003656:0.012931:0.006215:0.003656:0.007274:0.006215:0.012950:0.006215:0.007274:0.017857:0.012950:0.003656:0.003656:0.006196:0.017857:0.012411:0.003656:0.012315:0.012257:0.011507:0.003656:0.012315:0.006215:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.012411:0.005600:0.006215:0.012411:0.005850:0.006215:0.010853:0.008005:0.011368:0.005330
as it forms covalent bonds with a cysteine :@0.084848:0.673565:0.481076:0.673565:0.481076:0.657809:0.084848:0.657809:0.012950:0.007274:0.006542:0.003656:0.006331:0.006542:0.005850:0.012411:0.006131:0.017857:0.007274:0.006542:0.012257:0.012411:0.010468:0.012950:0.003656:0.012315:0.011545:0.006331:0.006542:0.012931:0.012411:0.011545:0.012989:0.007274:0.006542:0.015798:0.003656:0.006331:0.011545:0.006542:0.012950:0.006542:0.012257:0.010122:0.007274:0.006331:0.012315:0.003656:0.011545:0.012504:0.005330
residue in the BTK active site, inhibiting en-:@0.084848:0.689149:0.475737:0.689149:0.475737:0.673393:0.084848:0.673393:0.005521:0.012315:0.007274:0.003656:0.012989:0.011507:0.012315:0.006523:0.003656:0.011545:0.006523:0.006331:0.011545:0.012315:0.006523:0.010853:0.008005:0.011180:0.006523:0.012950:0.012257:0.006331:0.003656:0.010468:0.012315:0.006523:0.007274:0.003656:0.006331:0.012315:0.005138:0.006523:0.003656:0.011545:0.011545:0.003656:0.012931:0.003656:0.006331:0.003656:0.011545:0.012758:0.006523:0.012315:0.011545:0.006388
zyme activity.  BTK is a signalling molecule :@0.084848:0.704733:0.481087:0.704724:0.481087:0.688968:0.084848:0.688977:0.007986:0.010122:0.017857:0.012315:0.004984:0.012950:0.012257:0.006331:0.003656:0.010468:0.003656:0.006331:0.010122:0.005330:0.018118:0.004974:0.010853:0.008005:0.011180:0.004984:0.003656:0.007274:0.004984:0.012950:0.004974:0.007274:0.003656:0.012758:0.011545:0.012950:0.003656:0.003656:0.003656:0.011545:0.012758:0.004974:0.017857:0.012411:0.003656:0.012315:0.012257:0.011507:0.003656:0.012506:-0.023348
140:@0.209015:0.699105:0.227436:0.699105:0.227436:0.689920:0.209015:0.689920:0.006103:0.006103:0.006215
of the B-cell antigen receptor (BCR) and :@0.084840:0.720308:0.481078:0.720308:0.481078:0.704552:0.084840:0.704552:0.012411:0.005850:0.008909:0.006331:0.011545:0.012315:0.008909:0.010853:0.006196:0.012257:0.012315:0.003656:0.003656:0.008909:0.012950:0.011545:0.006331:0.003656:0.012758:0.012315:0.011545:0.008909:0.005521:0.012315:0.012257:0.012315:0.012931:0.006331:0.012411:0.005600:0.008909:0.006908:0.010853:0.015452:0.011488:0.006908:0.008909:0.012950:0.011545:0.013181:0.005330
cytokine receptor pathways. Ibrutinib in-:@0.084840:0.735892:0.475746:0.735892:0.475746:0.720136:0.084840:0.720136:0.012257:0.010122:0.006331:0.012411:0.009467:0.003656:0.011545:0.012315:0.011045:0.005519:0.012315:0.012257:0.012315:0.012931:0.006331:0.012411:0.005600:0.011045:0.012931:0.012950:0.006331:0.011545:0.015798:0.012950:0.010122:0.007274:0.005138:0.011045:0.004156:0.012931:0.005600:0.011507:0.006331:0.003656:0.011545:0.003656:0.012931:0.011045:0.003656:0.011545:0.006388
hibits malignant B-cell proliferation, survival, :@0.084840:0.751476:0.481051:0.751476:0.481051:0.735720:0.084840:0.735720:0.011545:0.003656:0.012931:0.003656:0.006331:0.007274:0.004607:0.017857:0.012950:0.003656:0.003656:0.012758:0.011545:0.012950:0.011545:0.006331:0.004609:0.010853:0.006196:0.012257:0.012315:0.003656:0.003656:0.004607:0.012931:0.005521:0.012411:0.003656:0.003656:0.005850:0.012315:0.005600:0.012950:0.006331:0.003656:0.012411:0.011545:0.005138:0.004607:0.007274:0.011507:0.005600:0.010468:0.003656:0.010468:0.012950:0.003656:0.005328:0.005330
cell migration and substrate adhesion.:@0.084840:0.767060:0.434051:0.767060:0.434051:0.751304:0.084840:0.751304:0.012257:0.012315:0.003656:0.003656:0.005138:0.017857:0.003656:0.012758:0.005600:0.012950:0.006331:0.003656:0.012411:0.011545:0.005138:0.012950:0.011545:0.012989:0.005138:0.007274:0.011507:0.012931:0.007274:0.006331:0.005600:0.012950:0.006331:0.012315:0.005138:0.012950:0.012989:0.011545:0.012315:0.007274:0.003656:0.012411:0.011545:0.005330
8. PROTEASOME INHIBITORS:@0.524242:0.079411:0.830923:0.079411:0.830923:0.059814:0.524242:0.059814:0.013170:0.006585:0.006585:0.013170:0.013641:0.019756:0.009878:0.012230:0.017404:0.012230:0.019756:0.021167:0.012230:0.006585:0.006585:0.017404:0.015993:0.006585:0.013641:0.006585:0.009878:0.019756:0.013641:0.012230
A proteasome is an enzyme complex that :@0.524242:0.097138:0.920514:0.097138:0.920514:0.081382:0.524242:0.081382:0.014239:0.005530:0.013123:0.005715:0.012604:0.006523:0.012508:0.013143:0.007466:0.012604:0.018049:0.012508:0.005542:0.003848:0.007466:0.005542:0.013143:0.011738:0.005542:0.012508:0.011738:0.008178:0.010314:0.018049:0.012508:0.005528:0.012450:0.012604:0.018049:0.013123:0.003848:0.012508:0.009236:0.005542:0.006523:0.011738:0.013143:0.006523:0.005330
plays an important role in the degradation :@0.524242:0.112576:0.920479:0.112576:0.920479:0.096820:0.524242:0.096820:0.013123:0.003848:0.013143:0.010314:0.007466:0.004541:0.013143:0.011738:0.004522:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.004522:0.005713:0.012604:0.003848:0.012508:0.004522:0.003848:0.011738:0.004522:0.006523:0.011738:0.012508:0.004522:0.013181:0.012508:0.012950:0.005792:0.013143:0.013181:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
of proteins involved in the cell cycle and :@0.524242:0.128015:0.920481:0.128015:0.920481:0.112259:0.524242:0.112259:0.012604:0.006042:0.007293:0.013123:0.005715:0.012604:0.006523:0.012508:0.003848:0.011738:0.007466:0.007293:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.007293:0.003848:0.011738:0.007293:0.006523:0.011738:0.012508:0.007293:0.012450:0.012508:0.003848:0.003848:0.007293:0.012450:0.010314:0.012450:0.003848:0.012508:0.007293:0.013143:0.011738:0.013181:0.005330
other cellular processes.  Bortezomib is a :@0.524242:0.143453:0.920487:0.143440:0.920487:0.127684:0.524242:0.127697:0.012604:0.006523:0.011738:0.012508:0.005792:0.007349:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.007370:0.013123:0.005715:0.012604:0.012450:0.012508:0.007466:0.007466:0.012508:0.007466:0.005330:0.012432:0.007370:0.011045:0.012604:0.005792:0.006523:0.012508:0.008178:0.012604:0.018049:0.003848:0.013123:0.007356:0.003848:0.007466:0.007370:0.013143:0.353665
26:@0.751895:0.137821:0.764325:0.137821:0.764325:0.128635:0.751895:0.128635:0.006215:0.006215
reversible proteasome inhibitor  capable :@0.524242:0.158878:0.920470:0.158878:0.920470:0.143123:0.524242:0.143123:0.005713:0.012508:0.010660:0.012508:0.005792:0.007466:0.003848:0.013123:0.003848:0.012508:0.011430:0.013123:0.005715:0.012604:0.006523:0.012508:0.013143:0.007466:0.012604:0.018049:0.012508:0.011430:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.005330:0.006090:0.012450:0.013143:0.013123:0.013143:0.013123:0.003848:0.012508:0.005330
of disrupting cellular processes involved in :@0.524242:0.174317:0.920493:0.174317:0.920493:0.158561:0.524242:0.158561:0.012604:0.006042:0.005796:0.013181:0.003848:0.007466:0.005792:0.011699:0.013123:0.006523:0.003848:0.011738:0.012950:0.005800:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.005811:0.013123:0.005715:0.012604:0.012450:0.012508:0.007466:0.007466:0.012508:0.007466:0.005811:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.005811:0.003848:0.011738:0.005330
the growth and survival of cancerous cells, :@0.524242:0.189755:0.920477:0.189755:0.920477:0.173999:0.524242:0.173999:0.006523:0.011738:0.012508:0.004256:0.012950:0.005711:0.012604:0.015990:0.006523:0.011738:0.004258:0.013143:0.011738:0.013181:0.004272:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.004272:0.012604:0.006042:0.004258:0.012450:0.013143:0.011738:0.012450:0.012508:0.005709:0.012604:0.011699:0.007466:0.004262:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.005330
leading to apoptosis.  Bortezomib is indi-:@0.524242:0.205194:0.915141:0.205176:0.915141:0.189420:0.524242:0.189438:0.003848:0.012508:0.013143:0.013181:0.003848:0.011738:0.012950:0.007658:0.006523:0.012604:0.007658:0.013143:0.013123:0.012604:0.013123:0.006523:0.012604:0.007466:0.003848:0.007466:0.005330:0.012440:0.007658:0.011045:0.012604:0.005792:0.006523:0.012508:0.008178:0.012604:0.018049:0.003848:0.013123:0.007658:0.003848:0.007466:0.007658:0.003848:0.011738:0.013181:0.003848:0.270272
26:@0.725138:0.199557:0.737568:0.199557:0.737568:0.190372:0.725138:0.190372:0.006215:0.006215
cated for::@0.524251:0.220615:0.617153:0.220615:0.617153:0.204859:0.524251:0.204859:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.006042:0.012604:0.005792:0.005330
13,51:@0.617128:0.214991:0.645095:0.214991:0.645095:0.205806:0.617128:0.205806:0.006215:0.006215:0.003107:0.006215:0.006215
n :@0.524242:0.233513:0.537571:0.233513:0.537571:0.225073:0.524242:0.225073:0.009762:0.003566
 :@0.554542:0.233513:0.558109:0.233513:0.558109:0.225073:0.554542:0.225073:0.003566
Primary treatment of multiple :@0.554545:0.236632:0.829502:0.236632:0.829502:0.220876:0.554545:0.220876:0.011392:0.005792:0.003848:0.018049:0.013143:0.005792:0.010314:0.005330:0.006523:0.005707:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.018049:0.011699:0.003848:0.006523:0.003848:0.013114:0.003848:0.012508:0.005330
myeloma in combination with :@0.554545:0.252071:0.837735:0.252071:0.837735:0.236315:0.554545:0.236315:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
melphalan and prednisone :@0.554545:0.267509:0.814165:0.267509:0.814165:0.251753:0.554545:0.251753:0.018049:0.012508:0.003848:0.013123:0.011738:0.013143:0.003848:0.013143:0.011738:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.005717:0.012508:0.013181:0.011738:0.003848:0.007466:0.012604:0.011738:0.012508:0.005330
n :@0.524242:0.280403:0.537571:0.280403:0.537571:0.271963:0.524242:0.271963:0.009762:0.003566
 :@0.554542:0.280403:0.558109:0.280403:0.558109:0.271963:0.554542:0.271963:0.003566
Monotherapy for multiple myeloma in :@0.554545:0.283522:0.910941:0.283522:0.910941:0.267766:0.554545:0.267766:0.017684:0.012604:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013112:0.010314:0.005330:0.006042:0.012604:0.005792:0.005330:0.018049:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.005330:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330
patients who have received at least :@0.554545:0.298961:0.896296:0.298961:0.896296:0.283205:0.554545:0.283205:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.005702:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.013181:0.005330:0.013143:0.006523:0.005330:0.003848:0.012508:0.013143:0.007466:0.006523:0.005330
one prior treatment and who have :@0.554545:0.314399:0.884181:0.314399:0.884181:0.298643:0.554545:0.298643:0.012604:0.011738:0.012508:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.006523:0.005690:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.013143:0.011738:0.013181:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330
progressive disease :@0.554545:0.330420:0.739878:0.330420:0.739878:0.314664:0.554545:0.314664:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330
n :@0.524242:0.343315:0.537571:0.343315:0.537571:0.334875:0.524242:0.334875:0.009762:0.003566
 :@0.554542:0.343315:0.558109:0.343315:0.558109:0.334875:0.554542:0.334875:0.003566
Treatment of patients with mantle-cell :@0.554545:0.346434:0.911963:0.346434:0.911963:0.330678:0.554545:0.330678:0.007620:0.005713:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012586:0.006042:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005321:0.018049:0.013143:0.011738:0.006523:0.003848:0.012508:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330
lymphoma who have received at :@0.554545:0.363050:0.873474:0.363050:0.873474:0.347294:0.554545:0.347294:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.005702:0.012508:0.012450:0.012508:0.003848:0.010660:0.012508:0.013181:0.005330:0.013143:0.006523:0.005330
least one prior therapy which includes :@0.554545:0.379666:0.913666:0.379666:0.913666:0.363910:0.554545:0.363910:0.003848:0.012508:0.013143:0.007466:0.006523:0.005330:0.012604:0.011738:0.012508:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.007466:0.005330
an anthracycline or mitoxantrone :@0.554545:0.396282:0.872574:0.396282:0.872574:0.380526:0.554545:0.380526:0.013143:0.011738:0.005330:0.013143:0.011738:0.006523:0.011738:0.005792:0.013143:0.012450:0.010314:0.012450:0.003848:0.003848:0.011738:0.012508:0.005330:0.012604:0.005792:0.005330:0.018049:0.003848:0.006523:0.012604:0.009236:0.013143:0.011738:0.006523:0.005686:0.012604:0.011738:0.012508:0.005330
and/or rituximab as part of a :@0.554545:0.412898:0.827633:0.412898:0.827633:0.397142:0.554545:0.397142:0.013143:0.011738:0.013181:0.008409:0.012604:0.005792:0.005330:0.005792:0.003848:0.006523:0.011699:0.009236:0.003848:0.018049:0.013143:0.013123:0.005330:0.013143:0.007466:0.005330:0.013123:0.013143:0.005792:0.006523:0.005330:0.012604:0.006042:0.005330:0.013143:0.005330
chemotherapy regimen:@0.554545:0.429513:0.777661:0.429513:0.777661:0.413757:0.554545:0.413757:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005696:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738
Side effects of bortezomib include nau-:@0.542422:0.446129:0.915167:0.446129:0.915167:0.430373:0.542422:0.430373:0.009583:0.003848:0.013181:0.012508:0.006562:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.007466:0.006562:0.012604:0.006042:0.006562:0.013123:0.012604:0.005792:0.006523:0.012508:0.008178:0.012604:0.018049:0.003848:0.013123:0.006546:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.006562:0.011738:0.013143:0.011699:0.006388
sea, diarrhoea, thrombocytopaenia, neu-:@0.524238:0.462745:0.915153:0.462745:0.915153:0.446989:0.524238:0.446989:0.007466:0.012508:0.013143:0.005330:0.005811:0.013181:0.003848:0.013143:0.005792:0.006344:0.011738:0.012604:0.012508:0.013143:0.005330:0.005811:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.012450:0.010314:0.006523:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.005811:0.011738:0.012508:0.011699:0.006388
tropaenia, peripheral neuropathy,  fa-:@0.524238:0.479361:0.915163:0.479361:0.915163:0.463605:0.524238:0.463605:0.006523:0.005709:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.019281:0.013123:0.012508:0.005792:0.003848:0.013123:0.011738:0.012508:0.005792:0.013143:0.003848:0.019281:0.011738:0.012508:0.011699:0.005707:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314:0.005330:0.005330:0.013941:0.006042:0.013143:0.006388
tigue,  neuralgia, anaemia, leukopaenia, :@0.524238:0.495977:0.920485:0.495977:0.920485:0.480221:0.524238:0.480221:0.006523:0.003848:0.012950:0.011699:0.012508:0.005330:0.005330:0.004664:0.011738:0.012508:0.011699:0.005792:0.013143:0.003848:0.012950:0.003848:0.013143:0.005330:0.010006:0.013143:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.010006:0.003848:0.012508:0.011699:0.009660:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.005330
constipation, vomiting, lymphopaenia, :@0.524238:0.512593:0.920478:0.512593:0.920478:0.496837:0.524238:0.496837:0.012450:0.012604:0.011738:0.007466:0.006523:0.003848:0.013123:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.020955:0.010660:0.012604:0.018049:0.003848:0.006523:0.003848:0.011738:0.012950:0.005330:0.020955:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.013123:0.013143:0.012508:0.011738:0.003848:0.013143:0.005330:0.005330
rash, pyrexia, and anorexia.:@0.524238:0.529208:0.782225:0.529208:0.782225:0.513452:0.524238:0.513452:0.005792:0.013143:0.007466:0.011738:0.005330:0.005330:0.013123:0.010314:0.005711:0.012508:0.009236:0.003848:0.013143:0.005330:0.005330:0.013143:0.011738:0.013181:0.005330:0.013143:0.011738:0.012604:0.005703:0.012508:0.009236:0.003848:0.013143:0.005330
51:@0.782229:0.523525:0.794659:0.523525:0.794659:0.514339:0.782229:0.514339:0.006215:0.006215
Contra-indications, special  precautions :@0.542424:0.545754:0.920491:0.545754:0.920491:0.529998:0.542424:0.529998:0.015644:0.012604:0.011738:0.006523:0.005792:0.013143:0.006388:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.008986:0.007466:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.005330:0.003670:0.013123:0.005713:0.012508:0.012450:0.013143:0.011699:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
and drug interactions: See :@0.524240:0.562369:0.778586:0.562369:0.778586:0.546614:0.524240:0.546614:0.013143:0.011738:0.013181:0.006408:0.013181:0.005792:0.011699:0.012950:0.006408:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.006408:0.009583:0.012508:0.012508:0.005330
MIMS Monthly, :@0.779663:0.562369:0.920479:0.562369:0.920479:0.546614:0.779663:0.546614:0.017684:0.004349:0.017684:0.009583:0.006408:0.017684:0.012604:0.011738:0.006523:0.011738:0.003848:0.010314:0.005330:0.005330
MDR:@0.524240:0.577808:0.567920:0.577808:0.567920:0.562052:0.524240:0.562052:0.017684:0.014316:0.011680
 or manufacturer’s product literature.:@0.567920:0.577808:0.913048:0.577808:0.913048:0.562052:0.567920:0.562052:0.005330:0.012604:0.005792:0.005330:0.018049:0.013143:0.011738:0.011699:0.006042:0.013143:0.012450:0.006523:0.011699:0.005694:0.012508:0.005792:0.006754:0.007466:0.005330:0.013123:0.005711:0.012604:0.013181:0.011699:0.012450:0.006523:0.005330:0.003848:0.003848:0.006523:0.012508:0.005792:0.013143:0.006523:0.011699:0.005698:0.012508:0.005330
DRUG-CLASS OVERVIEW:@0.084848:0.038601:0.357590:0.038601:0.357590:0.019343:0.084848:0.019343:0.017498:0.014276:0.015405:0.020508:0.007808:0.019121:0.010866:0.017404:0.011712:0.011712:0.006515:0.020438:0.016510:0.012606:0.013356:0.016510:0.005315:0.012606:0.022578